Oncology Contact Us

Article

CONTACT US

Editorial Inquiries:
Susan Beck
Executive Editor
Ph: 203-523-7084
Email: susan.beck@ubm.com

Editorial Office:
UBM Medica LLC
535 Connecticut Ave, Suite 300
Norwalk, CT 06854

Publisher and Sales Contacts:
Amy Birnbach
Group Publisher
Ph: 201-984-6265
Email: amy.birnbach@ubm.com

Sarah Mifsud
Account Manager
Digital Media
Ph: 203-523-7055
Email: sarah.mifsud@ubm.com

Web site Contact:
Ian Ingram
Managing Editor, cancernetwork.com
Email: ian.ingram@ubm.com

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.